Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pasithea Therapeutics Corp.

NASDAQ: KTTA · Life Sciences · 3 alerts · CIK 1841330

Share price
$0.5000Close, Nov 16
Market cap
$18.4M
Shares outstanding
36.75MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pasithea Therapeutics Corp. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Clinical Trial Data

Pasithea Therapeutics Clinical Trial Data

Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.

5:18 PM ET 10-Q
Financial Results

Pasithea Therapeutics Q3 2026 Results: Net Loss of $6.58M, Loss Widens

Pasithea Therapeutics Corp. reported a net loss of $14.7 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $11.1 million. The company maintained a cash position of $41.2 million as of the end of the period, down from $55.2 million at the start of the year.

Key figure
Net loss $6.58M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.